Clinical Trials Sponsored by Groupe Francophone des Myelodysplasies

Total 69 results

Groupe Francophone des Myelodysplasies

Active, not recruiting

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France, Italy
Groupe Francophone des Myelodysplasies

Completed

CPX-351 in Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Unknown

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Completed

Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS) (EPO-QoL)

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Unknown

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Completed

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

France
Groupe Francophone des Myelodysplasies

Unknown

Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid

Anemia in Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Recruiting

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (EPO-PRETAR)

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia Acute Myeloid

France
Groupe Francophone des Myelodysplasies

Completed

Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes

High Grade Myelodysplastic Syndrome Lesions

France, Tunisia
Groupe Francophone des Myelodysplasies

Unknown

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Completed

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Unknown

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies
Celgene

Completed

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

MDS | Systemic Autoimmune Diseases

France
Groupe Francophone des Myelodysplasies
Novartis

Unknown

A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS (GFM-EXVD-AZA)

MDS

France, Belgium
Groupe Francophone des Myelodysplasies
Celgene

Completed

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q (GFM-AZA-REV-09)

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (AVENHIR)

Chronic Myeloid Leukemia

France
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

AML | MDS

France
Groupe Francophone des Myelodysplasies
Celgene

Recruiting

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Myelodysplastic Syndromes | MDS

France
Groupe Francophone des Myelodysplasies
Novartis

Completed

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (LDE255)

MDS

France
Groupe Francophone des Myelodysplasies
GlaxoSmithKline; Novartis

Completed

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Thrombocytopenia | CMML

France
Groupe Francophone des Myelodysplasies
Celgene Corporation

Unknown

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q (GFM-Chimio-Rev)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

France
Groupe Francophone des Myelodysplasies
Aprea Therapeutics

Unknown

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations | Myelodysplastic Syndrome With Gene Mutation

France
Groupe Francophone des Myelodysplasies
EpiCept Corporation

Withdrawn

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies
Celgene Corporation

Terminated

A Phase II Study of Maintenance With Azacitidine in MDS Patients

Myelodysplastic Syndromes | Leukemia, Myelocytic, Acute

France
Groupe Francophone des Myelodysplasies
Astex Pharmaceuticals, Inc.

Active, not recruiting

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

AML | MDS

France
Groupe Francophone des Myelodysplasies
Novartis; Neovii Biotech

Active, not recruiting

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

MDS

France
Groupe Francophone des Myelodysplasies
Janssen-Cilag Ltd.

Completed

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML (GFM-DAC-CMML)

MDS

France
Groupe Francophone des Myelodysplasies
Roche Pharma AG

Completed

Erlotinib in Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

France
Groupe Francophone des Myelodysplasies
Teva Pharmaceuticals USA

Unknown

French Registry of First-line Treatment of Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia

France
Groupe Francophone des Myelodysplasies
Astex Pharmaceuticals, Inc.

Completed

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

MDS

France
Groupe Francophone des Myelodysplasies
Janssen-Cilag Ltd.

Completed

Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia

France
Groupe Francophone des Myelodysplasies
Genzyme, a Sanofi Company

Completed

Clofarabine in High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

France
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Terminated

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure (GFM-AZA-VOR)

Myelodysplastic Syndrome

France
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene

Completed

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Myelodysplastic Syndromes

France, Monaco
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Completed

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia (GFMVOR2007)

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies
Bristol-Myers Squibb; AbbVie

Recruiting

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Untreated Myelodysplastic Syndrome

France
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene Corporation

Completed

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies
Advancell - Advanced In Vitro Cell Technologies, S.A.

Terminated

GFM-Acadesine: A Phase I-II Trial of Acadesine (Acadesine)

SMD

France
GWT-TUD GmbH
Amsterdam UMC, location VUmc; BerGenBio ASA; Groupe Francophone des Myelodysplasies

Completed

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

Acute Myeloid Leukemia | High-risk Myelodysplastic Syndrome | Low-risk Myelodysplastic Syndrome

Germany, Netherlands, France
Intergroupe Francophone de Cancerologie Thoracique
Groupe Francais De Pneumo-Cancerologie

Completed

Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

France
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France; Gustave... and other collaborators

Completed

Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes (MDS04)

Myelodysplastic Syndromes

France
Intergroupe Francophone de Cancerologie Thoracique
Federation Francophone de Cancerologie Digestive; GERCOR - Multidisciplinary...

Active, not recruiting

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)

Neuroendocrine Carcinoma

France
GCP-Service International West GmbH
Saint-Louis Hospital, Paris, France; Groupe Francophone des Myelodysplasies; Australasian... and other collaborators

Recruiting

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Australia, France, Germany
Intergroupe Francophone de Cancerologie Thoracique
PharmaMar; Groupe Francais De Pneumo-Cancerologie

Completed

RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (LURBICLIN)

Small-cell Lung Cancer

France
Assistance Publique - Hôpitaux de Paris
Groupe Francophone Thrombose et Cancer

Terminated

Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy (PANCREADOGREL)

Metastatic Pancreatic Cancer | Locally Advanced Pancreatic Cancer | Adenocarcinoma, Pancreas

France
University Hospital, Montpellier
Grace Asso (Groupe francophone de Réhabilitation Améliorée après Chirurgie)

Recruiting

NIVATS Versus IGAVATS: a Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases (NIVATS-2)

Lung Diseases, Interstitial

France
Federation Francophone de Cancerologie Digestive
Intergroupe Francophone de Cancerologie Thoracique; ARCAGY/ GINECO GROUP; GERCOR... and other collaborators

Completed

The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients (CACOVID-19)

Cancer | Chemotherapy | Solid Tumor | Surgery | COVID | Radiotherapy | Immunotherapy | Social Inequality | French National Cohort

France
Intergroupe Francophone de Cancerologie Thoracique
University Hospital, Caen; Groupe Francais De Pneumo-Cancerologie

Completed

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study (MAPS)

Mesothelioma

France

Clinical Trials Sponsored by Groupe Francophone des Myelodysplasies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations